Stocks股票 / Health Care / ACAD
Acadia Pharmaceuticals · Health Care
ACAD US listed · USD美股 · 美元
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.阿卡迪亚制药公司（Acadia Pharmaceuticals Inc. ）是一家生物制药公司，总部位于加利福尼亚州德尔马。
Mid cap中盘 · $4B
Mixed profile混合特征
Health Care
S&P 600标普600小盘Russell 2000罗素2000
$25.09
-$0.51 · -1.99%
52w low52周低 $19.65high高 $28.49
Lagging — relative weakness落后 — 相对弱势
The bottoming setup is not yet confirmed (price still below the 10-day average) and oscillators are already extended/overbought — not a safe entry. Wait for…筑底形态尚未确认（价格仍位于 10 日均线下方），且摆动指标已过热——此处入场风险较高。等待价格收复 10 日均线且动量趋于稳定后再考虑建仓。
Engine read引擎解读 · 2026-07-21
Price chart价格图表
daily · interactive日线 · 可交互
Open in Terminal打开终端 ↗
Loading chart…图表加载中…
The interactive chart could not load here.互动图表暂时无法在此加载。
Open the live chart in Terminal在终端中打开实时图表 ↗
Candles, volume and moving averages — pan and zoom inside the chart.蜡烛图、成交量与均线 — 图内可缩放拖动。
MMastermind Terminal — live & interactiveMastermind 终端 — 实时互动 ↗
Technicals技术面
daily bars日线数据 · 2026-07-21
Momentum (RSI 14)动量（RSI 14）
56
Neutral zone中性区域
vs 50-day average相对50日均线
+9.4% above上方
Uptrend intact趋势完好
vs 200-day average相对200日均线
+7.1% above上方
Long trend up长期向上
Volatility波动率
40th percentile第40百分位
These readings feed the stance at the top — one source per number, refreshed nightly.以上读数构成页首的引擎立场 — 每个数字只有一个来源，每晚更新。
Earnings财务业绩
next report下次财报 2026-08-0516days to go天后公布
Estimates being cut预期下调
Valuation估值
Roughly fair vs sector相对行业估值合理| Multiple指标 | ACAD | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率（历史） | 10.93x | 28.59 | |
| P/B市净率 | 3.48x | 3.44 | |
| P/S市销率 | 3.99x | 2.97 | |
| Earnings yield盈利收益率 | 9.15% | 2.72 | |
| FCF yield自由现金流收益率 | 2.46% | 4.00 | |
| EV/EBITDA企业价值/EBITDA | 38.75x | 18.18 | |
| P/FCF市值/自由现金流 | 40.64x | 22.08 |
"Cheaper than" = share of sector peers trading richer on that multiple.「相对便宜」= 行业中该指标估值更高的同行占比。
Financials财务数据
fiscal years财年Revenue营业收入
5-yr growth5年复合增速 19.4%
Earnings per share每股收益
Free cash flow自由现金流
Operating margin营业利润率
9.8%
Net margin净利率
36.5%
FCF margin自由现金流利润率
10.3%
Balance-sheet quality财务体质 5/8
Bankruptcy risk: safe zone破产风险：安全区
Return on equity股本回报率 32%
Warning警示
Leverage杠杆
Net debt / EBITDA净债务/EBITDA-1.68
Current ratio流动比率3.83
Capital allocation资本配置
Stock-based comp股权薪酬$52.1M
Share count change (1y)股数变化（1年）+2.2%
Why is it moving为何波动
6 checks · nightly六项检查 · 每晚
Macro宏观
Long-duration name into a restrictive, rising-real-rate regime → rate headwind.长久期标的进入偏紧、实际利率上行的环境→利率逆风。
Positioning持仓
Insider cluster activity内部人集中交易
Technical技术面
ACAD daily MACD crossed downACAD 日线MACD下穿
Ownership & smart money持仓与聪明钱
13FInsider activity:内部人动向： -$1.8M net (0 buyers, 6 sellers)-$1.8M 净值（0 买家，6 卖家）
Concentrated ownership集中持仓
| Fund基金 | Grade评级 | Latest move最新动作 | % of book组合占比 | As of截至 |
|---|---|---|---|---|
| Baker Bros. Advisors | A | Holding持有 | 5.5% | 2026-03-31 |
| RTW Investments | B | Holding持有 | 1.6% | 2026-03-31 |
Signal history信号历史
engine events引擎事件
NEARING A HIGH → BOTTOMING接近高点 → 筑底中
BUY SETUP. Buyers rejected the 2026-06-16 low (swing low printed) but price hasn't reclaimed its 10-day average — first box ticked, not all. Last cycle was left-translated (topped early) — a bearish structural tell买入预备。买方拒绝了 2026-06-16 的低点（摆动低点已现），但价格尚未收复 10 日均线——第一项条件达成，并非全部。 上一周期为左移结构（见顶偏早）——属于看空的结构性信号
Jul 16, 2026
ACAD daily MACD crossed downACAD 日线MACD下穿
The daily MACD histogram turned negative — fast and noisy, context rather than a standalone trigger. $25.63.日线MACD柱状图转负 — 快速且嘈杂，仅作背景。$25.63。
Jul 15, 2026
BOTTOMING → NEARING A HIGH筑底中 → 接近高点
TAKE PROFITS止盈
Jul 15, 2026
ACAD took relative-strength leadershipACAD 取得相对强弱领先
Relative strength vs SPY crossed above the 90th percentile of the last 90 days — leadership tends to persist. $25.92.相对标普500的强弱上穿近90日的第90百分位 — 领先往往延续。$25.92。
Jul 13, 2026
UPTREND → BOTTOMING上涨趋势 → 筑底中
BUY SETUP买入预备
Jul 7, 2026
NEARING A HIGH → UPTREND接近高点 → 上涨趋势
HOLD持有
Jul 6, 2026
UPTREND → NEARING A HIGH上涨趋势 → 接近高点
TAKE PROFITS止盈
Jul 2, 2026
NEARING A HIGH → UPTREND接近高点 → 上涨趋势
HOLD持有
Jul 2, 2026
ACAD took relative-strength leadershipACAD 取得相对强弱领先
Relative strength vs SPY crossed above the 90th percentile of the last 90 days — leadership tends to persist. $25.97.相对标普500的强弱上穿近90日的第90百分位 — 领先往往延续。$25.97。
Jul 1, 2026
UPTREND → NEARING A HIGH上涨趋势 → 接近高点
TAKE PROFITS止盈
Showing the last 15 of显示最近15条，共 248 signals条信号
Company profile公司档案
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.阿卡迪亚制药公司（Acadia Pharmaceuticals Inc. ）是一家生物制药公司，总部位于加利福尼亚州德尔马。
Style DNA — how it trades vs the market风格基因 — 相对市场的交易特征
Value价值
Below market低于市场
Quality质量
Below market低于市场
Investment资本投入
Below market低于市场
Low volatility低波动
Below market低于市场
Low market beta低市场敏感度
Below market低于市场
Earnings quality盈利质量
Above market高于市场
Short interest空头兴趣
Below market低于市场
Watch items — what could change the story关注项 — 可能改变故事的因素
- Receivables stretch
- Capital intensity rising
The whole US universe — S&P 1500 and Russell 2000 — read nightly.覆盖标普1500与罗素2000全部成分股 — 每晚更新解读。
Signals, options positioning, smart-money moves and factor DNA — the same engine that wrote this page covers 2,700+ US stocks.信号、期权持仓、聪明钱动向与因子基因 — 撰写本页的引擎覆盖2700多只美股。
Statistics — full detail统计数据 — 完整明细
Valuation vs sector估值对比行业
| Multiple指标 | This stock本股 | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率（静态） | 10.9× | 28.6× | 95% |
| Price / Book市净率 | 3.5× | 3.4× | 47% |
| Price / Sales市销率 | 4.0× | 3.0× | 37% |
| EV / EBITDAEV/EBITDA | 38.8× | 18.2× | 14% |
| Earnings yield盈利收益率 | 9.2% | 2.7% | 97% |
| Free-cash-flow yield自由现金流收益率 | 2.6% | 5.5% | 20% |
Relative strength相对强度
vs market, 1 month相对大盘（1个月）
31/100 — middle of the pack居中
vs market, 3 months相对大盘（3个月）
70/100 — stronger than most强于多数
vs market, 6 months相对大盘（6个月）
29/100 — weaker than most弱于多数
vs market, 12 months相对大盘（12个月）
45/100 — middle of the pack居中
Rank in sector行业内排名
#110 / 165
0–100 percentile of total return vs all covered stocks.总回报在全部覆盖股票中的百分位（0–100）。
Price history价格历史
| Period周期 | This stock本股 | S&P 500标普500 |
|---|---|---|
| 1 Week近1周 | -1.6% | -0.9% |
| 1 Month近1月 | +16.0% | -0.6% |
| 3 Months近3月 | +15.1% | +5.4% |
| 6 Months近6月 | -6.2% | +8.6% |
| Year to date年初至今 | -4.6% | +8.9% |
| 1 Year近1年 | +11.2% | +19.2% |
| 3 Years近3年 | -18.5% | +69.9% |
Trading information交易信息
Beta vs market贝塔
0.95
Volatility rank波动率分位
40th pctile
Short interest空头占比
6.4% of float
Market cap市值
$4B
EPS (trailing)每股收益
$2.30
Off 52-week high距52周高点
-10.6%
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Financials — full detail财务数据 — 完整明细
Multi-year record多年财务记录
| 20202020 | 20212021 | 20222022 | 20232023 | 20242024 | 20252025 | |
|---|---|---|---|---|---|---|
| Revenue营业收入 | $442M | $484M | $517M | $726M | $958M | $1.1B |
| EPS每股收益 | $-1.79 | $-1.05 | $-1.34 | $-0.37 | $1.36 | $2.30 |
| Free cash flow自由现金流 | $-144M | $-127M | $-114M | $17M | $157M | $105M |
| Gross margin毛利率 | 97.7% | 97.8% | 98.0% | 94.3% | 91.5% | 91.7% |
| Net margin净利率 | -63.7% | -34.7% | -41.8% | -8.4% | 23.6% | 36.5% |
| FCF margin自由现金流利润率 | -32.5% | -26.2% | -22.0% | 2.3% | 16.4% | 9.8% |
Latest fiscal year最近财年
Revenue (FY)营业收入（财年）
$1.1B
Net income净利润
$391M
Operating cash flow经营现金流
$110M
Total assets总资产
$1.6B
Shareholder equity股东权益
$1.2B
Shares outstanding总股本
0.17B
Returns & growth回报与增长
Return on equity股本回报率
31.9%
Return on assets资产回报率
25.0%
Profit growth利润增速
+73.0%
Asset growth资产增速
+31.7%
Accounting quality checks会计质量检查
- Earnings quality: accruals trending up over 6 fiscal years — earnings increasingly not cash-backed盈利质量：应计利润在 6 个财年间走高——盈利的现金支撑减弱
- Working capital: inventory +1050% vs sales +143% — inventory building, demand risk营运资本：存货 +1050% 对销售 +143%——存货积压，需求风险
- Pricing power: gross margin −6.0pts over 6 years定价能力：毛利率 6 年下降 6.0 个百分点
- Capital discipline: share count +6.7% over 6 years (dilution)资本纪律：股本 6 年增加 6.7%（稀释）
- Balance sheet: Altman Z 7.5 — safe zone资产负债表：Altman Z 7.5——安全区
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Technicals — full detail技术面 — 完整明细
Indicator readings指标读数
RSI (14-day)RSI（14日）
56
RSI (2-day)RSI（2日）
9
vs 20-day average相对20日均线
-0.2%
vs 50-day average相对50日均线
+9.4%
vs 200-day average相对200日均线
+7.1%
Golden cross (50>200)金叉（50>200）
not in effect未生效
MACDMACD
below signal位于信号线下方
Timeframe alignment多周期共振
Daily日线
momentum down — fresh downturn动能向下——刚刚转弱
3-day3日线
momentum up动能向上
Weekly周线
momentum up动能向上
When daily through monthly point the same way, moves carry further.当日线到月线方向一致时，行情往往更有延续性。
Volatility regime波动状态
Range width percentile波幅宽度分位
73/100
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Earnings — full detail财务业绩 — 完整明细
Estimate revisions预期修正
Analysts covering覆盖分析师
1
Estimate direction预期调整方向
mostly cutting多数下调
Estimate change, 90 days预期变化（90天）
-6.1%
Net upgrades, 30 days净上调（30天）
-1
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Ownership — full detail持仓 — 完整明细
Tracked funds holding it跟踪基金持仓
| Fund基金 | Grade评级 | Latest move最新动作 | % of book组合占比 | Position市值 |
|---|---|---|---|---|
| Baker Bros. Advisors | A | Holding持有 | 5.5% | $955M |
| RTW Investments | B | Holding持有 | 1.6% | $159M |
Fund positioning基金持仓概览
Tracked funds in the name持有该股的跟踪基金
2
Buying vs selling买入vs卖出
0 : 0
Quarterly trend季度趋势
{'direction': 'distributing', 'n_quarters': 14, 'holders_first': 3, 'holders_last': 0, 'holders_delta': -3, 'value_change_pct': -100.0, 'from_period': '2023-03-31', 'to_period': '2026-06-30', 'available_on': '', 'available_on_first': '2023-05-15', 'holders_series': [3, 3, 2, 3, 2, 2, 2, 2, 2, 2, 2, 2, 2, 0]}{'direction': 'distributing', 'n_quarters': 14, 'holders_first': 3, 'holders_last': 0, 'holders_delta': -3, 'value_change_pct': -100.0, 'from_period': '2023-03-31', 'to_period': '2026-06-30', 'available_on': '', 'available_on_first': '2023-05-15', 'holders_series': [3, 3, 2, 3, 2, 2, 2, 2, 2, 2, 2, 2, 2, 0]}
Insiders & shorts内部人与空头
Insider net buying (6 months)内部人净买入（6个月）
-$1.8M
Insider buyers vs sellers内部人买家vs卖家
0 : 6
Short interest空头占流通盘
6.4%
Days to cover回补天数
4.8
Short interest change空头变化
-7.3%
Recent fund flows近期基金流向
SPDR S&P BiotechSPDR S&P Biotech
trimming减持
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。
Seasonality — full detail季节性 — 完整明细
Strongest month最强月份
Dec · 100%
Weakest month最弱月份
Mar · 0%
Month by month逐月统计
| Month月份 | Closed higher收涨占比 | Median move中位涨跌 | Years年数 |
|---|---|---|---|
| Jan1月 | 33% | -5.8% | 3 |
| Feb2月 | 33% | -1.6% | 3 |
| Mar3月 | 0% | -16.0% | 3 |
| Apr4月 | 33% | -9.8% | 3 |
| May5月 | 33% | -3.1% | 3 |
| Jun6月 | 75% | +7.8% | 4 |
| Jul7月 | 75% | +16.2% | 4 |
| Aug8月 | 33% | -7.3% | 3 |
| Sep9月 | 0% | -18.7% | 3 |
| Oct10月 | 67% | +6.8% | 3 |
| Nov11月 | 67% | +10.4% | 3 |
| Dec12月 | 100% | +13.1% | 3 |
History is a tendency, not a promise — small samples wobble.历史规律只是倾向而非保证 — 样本少时波动大。
Research context only — refreshed nightly. Not investment advice.仅供研究参考 — 每晚更新，不构成投资建议。